v3.21.1
Segment Information - Disaggregation of Revenue (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Disaggregation of Revenue    
Total net revenues $ 13,010 $ 8,619
All other (a)    
Disaggregation of Revenue    
Net revenues 892 553
Immunology | Humira    
Disaggregation of Revenue    
Net revenues 4,867 4,703
Immunology | Humira | United States    
Disaggregation of Revenue    
Net revenues 3,907 3,656
Immunology | Humira | International    
Disaggregation of Revenue    
Net revenues 960 1,047
Immunology | Skyrizi    
Disaggregation of Revenue    
Net revenues 574 300
Immunology | Skyrizi | United States    
Disaggregation of Revenue    
Net revenues 481 266
Immunology | Skyrizi | International    
Disaggregation of Revenue    
Net revenues 93 34
Immunology | Rinvoq    
Disaggregation of Revenue    
Net revenues 303 86
Immunology | Rinvoq | United States    
Disaggregation of Revenue    
Net revenues 245 82
Immunology | Rinvoq | International    
Disaggregation of Revenue    
Net revenues 58 4
Hematologic Oncology | Imbruvica    
Disaggregation of Revenue    
Net revenues 1,268 1,232
Hematologic Oncology | Imbruvica | United States    
Disaggregation of Revenue    
Net revenues 999 966
Hematologic Oncology | Imbruvica | International    
Disaggregation of Revenue    
Collaboration revenues 269 266
Hematologic Oncology | Venclexta    
Disaggregation of Revenue    
Net revenues 405 317
Hematologic Oncology | Venclexta | United States    
Disaggregation of Revenue    
Net revenues 225 201
Hematologic Oncology | Venclexta | International    
Disaggregation of Revenue    
Net revenues 180 116
Aesthetics | Botox Cosmetic    
Disaggregation of Revenue    
Net revenues [1] 477 0
Aesthetics | Botox Cosmetic | United States    
Disaggregation of Revenue    
Net revenues [1] 305 0
Aesthetics | Botox Cosmetic | International    
Disaggregation of Revenue    
Net revenues [1] 172 0
Aesthetics | Juvederm Collection    
Disaggregation of Revenue    
Net revenues [1] 321 0
Aesthetics | Juvederm Collection | United States    
Disaggregation of Revenue    
Net revenues [1] 123 0
Aesthetics | Juvederm Collection | International    
Disaggregation of Revenue    
Net revenues [1] 198 0
Aesthetics | Other Aesthetics    
Disaggregation of Revenue    
Net revenues [1] 343 0
Aesthetics | Other Aesthetics | United States    
Disaggregation of Revenue    
Net revenues [1] 300 0
Aesthetics | Other Aesthetics | International    
Disaggregation of Revenue    
Net revenues [1] 43 0
Neuroscience | Botox Therapeutic    
Disaggregation of Revenue    
Net revenues [1] 532 0
Neuroscience | Botox Therapeutic | United States    
Disaggregation of Revenue    
Net revenues [1] 429 0
Neuroscience | Botox Therapeutic | International    
Disaggregation of Revenue    
Net revenues [1] 103 0
Neuroscience | Vraylar | United States    
Disaggregation of Revenue    
Net revenues [1] 346 0
Neuroscience | Duodopa    
Disaggregation of Revenue    
Net revenues 129 124
Neuroscience | Duodopa | United States    
Disaggregation of Revenue    
Net revenues 25 25
Neuroscience | Duodopa | International    
Disaggregation of Revenue    
Net revenues 104 99
Neuroscience | Ubrelvy | United States    
Disaggregation of Revenue    
Net revenues [1] 81 0
Neuroscience | Other Neuroscience    
Disaggregation of Revenue    
Net revenues [1] 160 0
Neuroscience | Other Neuroscience | United States    
Disaggregation of Revenue    
Net revenues [1] 156 0
Neuroscience | Other Neuroscience | International    
Disaggregation of Revenue    
Net revenues [1] 4 0
Eye Care | Lumigan/Ganfort    
Disaggregation of Revenue    
Net revenues [1] 143 0
Eye Care | Lumigan/Ganfort | United States    
Disaggregation of Revenue    
Net revenues [1] 66 0
Eye Care | Lumigan/Ganfort | International    
Disaggregation of Revenue    
Net revenues [1] 77 0
Eye Care | Alphagan/Combigan    
Disaggregation of Revenue    
Net revenues [1] 118 0
Eye Care | Alphagan/Combigan | United States    
Disaggregation of Revenue    
Net revenues [1] 80 0
Eye Care | Alphagan/Combigan | International    
Disaggregation of Revenue    
Net revenues [1] 38 0
Eye Care | Restasis    
Disaggregation of Revenue    
Net revenues [1] 280 0
Eye Care | Restasis | United States    
Disaggregation of Revenue    
Net revenues [1] 267 0
Eye Care | Restasis | International    
Disaggregation of Revenue    
Net revenues [1] 13 0
Eye Care | Other Eye Care    
Disaggregation of Revenue    
Net revenues [1] 276 0
Eye Care | Other Eye Care | United States    
Disaggregation of Revenue    
Net revenues [1] 117 0
Eye Care | Other Eye Care | International    
Disaggregation of Revenue    
Net revenues [1] 159 0
Women's Health | Lo Loestrin    
Disaggregation of Revenue    
Net revenues [1] 104 0
Women's Health | Lo Loestrin | United States    
Disaggregation of Revenue    
Net revenues [1] 102 0
Women's Health | Lo Loestrin | International    
Disaggregation of Revenue    
Net revenues [1] 2 0
Women's Health | Orilissa/Oriahnn    
Disaggregation of Revenue    
Net revenues 30 31
Women's Health | Orilissa/Oriahnn | United States    
Disaggregation of Revenue    
Net revenues 29 30
Women's Health | Orilissa/Oriahnn | International    
Disaggregation of Revenue    
Net revenues 1 1
Women's Health | Other Women's Health    
Disaggregation of Revenue    
Net revenues [1] 46 0
Women's Health | Other Women's Health | United States    
Disaggregation of Revenue    
Net revenues [1] 46 0
Women's Health | Other Women's Health | International    
Disaggregation of Revenue    
Net revenues [1] 0 0
Other Key Products | Mavyret    
Disaggregation of Revenue    
Net revenues 415 559
Other Key Products | Mavyret | United States    
Disaggregation of Revenue    
Net revenues 170 234
Other Key Products | Mavyret | International    
Disaggregation of Revenue    
Net revenues 245 325
Other Key Products | Creon | United States    
Disaggregation of Revenue    
Net revenues 274 276
Other Key Products | Lupron    
Disaggregation of Revenue    
Net revenues 213 233
Other Key Products | Lupron | United States    
Disaggregation of Revenue    
Net revenues 171 195
Other Key Products | Lupron | International    
Disaggregation of Revenue    
Net revenues 42 38
Other Key Products | Linzess/Constella    
Disaggregation of Revenue    
Net revenues [1] 222 0
Other Key Products | Linzess/Constella | United States    
Disaggregation of Revenue    
Net revenues [1] 215 0
Other Key Products | Linzess/Constella | International    
Disaggregation of Revenue    
Net revenues [1] 7 0
Other Key Products | Synthroid | United States    
Disaggregation of Revenue    
Net revenues $ 191 $ 205
[1] (a) Net revenues include Allergan product revenues after the acquisition closing date of May 8, 2020.